X4 Pharmaceuticals, Inc. XFOR

Company Overview

X4 Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on the discovery, development, and commercialization of therapies for rare diseases and primary immunodeficiencies. The company’s core scientific focus is modulation of the CXCR4 chemokine receptor pathway, which is involved in immune system function, inflammation, and hematopoietic cell trafficking. X4 operates within the biotechnology and specialty pharmaceutical industries, with an emphasis on genetically defined and underserved patient populations.

The company’s primary commercial and development efforts center on mavorixafor, an oral CXCR4 antagonist developed for chronic neutropenic disorders and other rare immune-related conditions. X4’s strategy has centered on leveraging its CXCR4 platform to address diseases with limited approved treatment options. Founded in 2014 and headquartered in Boston, Massachusetts, the company evolved from an early-stage research organization into a clinical-stage and subsequently commercial-stage biotechnology company through public financing, strategic licensing activities, and advancement of late-stage clinical programs documented in SEC filings and corporate investor materials.